LKFT
Galapagos N.V. Sponsored ADR
NASDAQ · Healthcare · Biotechnology · US
$29.79
−0.37%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -96.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +66.4%
- EBITDA
- +352.6%
- EBIT
- +366.2%
- Net income
- +23.1%
- EPS
- +23.2%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026